Eledon Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.26
- Today's High:
- $1.35
- Open Price:
- $1.3305
- 52W Low:
- $1.65
- 52W High:
- $3.928
- Prev. Close:
- $1.32
- Volume:
- 32485
Company Statistics
- Market Cap.:
- $44.34 million
- Book Value:
- 5.429
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -21.05%
- Return on Equity TTM:
- -76.91%
Company Profile
Eledon Pharmaceuticals Inc had its IPO on 2014-09-17 under the ticker symbol ELDN.
The company operates in the Healthcare sector and Biotechnology industry. Eledon Pharmaceuticals Inc has a staff strength of 17 employees.
Stock update
Shares of Eledon Pharmaceuticals Inc opened at $1.33 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.26 - $1.35, and closed at $1.27.
This is a -3.79% slip from the previous day's closing price.
A total volume of 32,485 shares were traded at the close of the day’s session.
In the last one week, shares of Eledon Pharmaceuticals Inc have slipped by -9.93%.
Eledon Pharmaceuticals Inc's Key Ratios
Eledon Pharmaceuticals Inc has a market cap of $44.34 million, indicating a price to book ratio of 0.2477 and a price to sales ratio of 0.
In the last 12-months Eledon Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-36862000. The EBITDA ratio measures Eledon Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Eledon Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -21.05% with a return of equity of -76.91%.
In Q1, Eledon Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Eledon Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 2.1896
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-6.86 per share while it has a forward price to earnings multiple of 2.1896 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eledon Pharmaceuticals Inc’s profitability.
Eledon Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.7763. Its price to sales ratio in the trailing 12-months stood at 0.
Eledon Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $82.31 million
- Total Liabilities
- $5.48 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Eledon Pharmaceuticals Inc ended 2025 with $82.31 million in total assets and $0 in total liabilities. Its intangible assets were valued at $82.31 million while shareholder equity stood at $74.79 million.
Eledon Pharmaceuticals Inc ended 2025 with $1.75 million in deferred long-term liabilities, $5.48 million in other current liabilities, 14000.00 in common stock, $-213637000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $46.49 million and cash and short-term investments were $46.49 million. The company’s total short-term debt was $384,000 while long-term debt stood at $0.
Eledon Pharmaceuticals Inc’s total current assets stands at $48.90 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.85 million and inventory worth $0.
In 2025, Eledon Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Eledon Pharmaceuticals Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $1.27
- 52-Week High
- $3.928
- 52-Week Low
- $1.65
- Analyst Target Price
- $18.4
Eledon Pharmaceuticals Inc stock is currently trading at $1.27 per share. It touched a 52-week high of $3.928 and a 52-week low of $3.928. Analysts tracking the stock have a 12-month average target price of $18.4.
Its 50-day moving average was $1.36 and 200-day moving average was $2.13 The short ratio stood at 0.06 indicating a short percent outstanding of 0%.
Around 1005.9% of the company’s stock are held by insiders while 4865.9% are held by institutions.
Frequently Asked Questions About Eledon Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.